HealthDoc LLc

SCIENCE FOR BETTER LIVING

IMPROVE THE PROVEN PATH WITH HYBRID NANO-ENGINEERING

Make it better Make it Economic So can be used by all

Forward-looking Statements

- This presentation includes or incorporates by reference statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements include, but are not limited to information or assumptions about expenses, capital and other expenditures, financing plans, capital structure, cash flow, liquidity, management's plans, goals and objectives for future operations and growth. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases beyond our control and which could cause actual performance or results to differ materially from those expressed in or suggested by forward-looking statements.
- Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to Health ability to successfully further commercialize its VAZALORE products; the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx's proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; developments and projections relating to our competitors or our industry; risks that PLx may lack the financial resources and access to capital to fund proposed operations; the impact of difficult macroeconomic conditions, such as inflation and reductions in consumer spending, on the demand for PLx's products; and risks relating to PLx's ability to identify, evaluate and complete any strategic alternative that yields value for its stockholders.
- Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to undertake or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as

OUR MISSION

HealthDoc is focused on improving the performance of established therapeutic agents with its proprietary drug delivery platform

We are driven to transform the standard of care for millions of patients with economic, safe and more effective formulations

Economic Patented Better formulation Open market Multi B\$	The most inexpensive nano technology ever been used for manufacturing of Nano medicines	
	Patent protection for 15 years to beat the genetic cliff	
	Formulation is more effective and less toxic. Consistent bioavailability independent of food	
	The US generic drug market size reached US\$ 86.9 Billion in 2022 . Looking forward, IMARC Group expects the market to reach US\$ 110.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4% during 2023-2028	
	167 drug formulations in pipeline	

Lead Products Using Hybrid Nano-Engineering


Nano Aspirin Capsule : AsCurin


For over 40 million patients at risk for another vascular event and for temporary pain relief Fast and reliable platelet inhibition Fewer gastric erosions and ulcers Large OTC opportunity with a \$10 billion retail market Strong patent protection for all formulations

Unique Aspirin Delivery System


With AsCurin patients will receive all the benefits of immediate-release aspirin + PLUS added safety and efficacy

- . Bioequivalent to immediate-release/plain aspirin
- . Specially designed to help protect the stomach





Protect local GI injury




Efficacy

Safety : No GI injury



Non treated




AsCurin treated

cGMP Manufacturing

Material is produced under cGMP guideline in FDA approved facility, USA And can be produced in tons quantity at an affordable price to compete Any nano aspirin and even the regular Aspirin Offering a better product at same price


Buchi B290 Prototype- Testing (pXRD)



 pXRD diffractogram of the spray dried dispersion material shows no residual crystalline peaks indicative of amorphous nature of the components in the formulation

Buchi B290 Prototype- Testing (PSD and density)

- Bulk density of SDD was measured to be 0.22g/mL.
- Tapped density measured to be 0.42g/mL.



Opportunity for Innovation in Aspirin Delivery


Aspirin erratically absorbed from the GI tract


Plain Aspirin is associated with Local GI injury AsCurin a water soluble Nano formulation is perfect option

U.S. Market Opportunity For Nano-Aspirin More than 10 Billion \$

Vascular Patients: Patients with Atherosclerotic Cardiovascular Disease (ASCVD) defined by having a previous event such as heart attack or stroke or a previous procedure such as cardiac stent, bypass operation, carotid operation or who have imaging evidence of significant vascular disease such as ultrasound, angiogram, etc.
Diabetic Patients: Patients with diabetes but without evidence of ASCVD

•Diabetic Patients: Patients with diabetes but without evidence of ASCVL who are candidates for aspirin therapy.





AsCurin can reduce your Risk of another heart attack by 31% AsCurin can help prevent another clot-related Stroke by 22% ACHES and PAIN Control safely With AsCurin


HealthDoc Investment Highlights

Unique Drug Delivery Platform Enhance delivery with optimized absorption, reducing risk of local stomach injury; extended patent life through 2036
Utilize the often faster and lower cost 505(b)(2) NDA regulatory path

Commercial-Stage Lead Product AsCurin 1st Nano-*Aspirin capsule:*

Fast, reliable absorption for pain relief plus the life-saving benefits
AsCurin allows for nano release of aspirin, limiting its side effects

Large Addressable Market Opportunity Over \$10 billion retail market opportunity for AsCurin:Million patients at risk for vascular disease, pain and inflammation.



- 1.Ascriptin
- 2.Aspergum
- 3.Aspirtab
- 4.Bayer
- 5.Easprin
- 6.Ecotrin
- 7.Ecpirin
- 8.Entercote
- 9.Genacote
- 10.Halfprin
- 11.Ninoprin
- 12.Norwich Aspirin

- : NOVARTIS
 - : Retrobrands USA LLC
 - : GERI-CARE PHARMACEUTICALS